- Tempus | AI-enabled precision medicine
Tempus has built the world’s largest library of clinical molecular data and an operating system to make that data accessible and useful, starting with cancer
- Tempus AI - Wikipedia
Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM " [6][7]
- Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?
Tempus AI has over 400 petabytes of healthcare data, which can be highly valuable when training AI models
- Tempus | SoftBank Group Corp.
Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world Having built its platform for oncology, it has expanded to neuropsychiatry, cardiology, infectious disease, and radiology
- Tempus AIs Data Business Is Expanding and Adding to Revenues: Heres . . .
TEM's surging Insights revenues, new contracts and expanded AI capabilities highlight its shift toward scalable data-driven growth
- Providers - Tempus
For clinicians associated with advanced research initiatives, Tempus provides next-generation genomic profiling, biological organoid modeling, image pattern AI recognition, and a range of clinical trial and research collaborations
- Our Technology - Tempus
We’re building innovative tech solutions oriented around clinical care and research products—and the virtuous cycle between them A desktop and mobile platform for ordering, managing, and receiving Tempus tests and patient results Review test results and build custom cohorts
- Home - Tempus Unlimited
Tempus Unlimited exists to provide a continuum of community based services that support the efforts of children and adults with disabilities to live as independently as possible in the least restrictive environment
|